Redeye provides a research update following the Q2 report published by OncoZenge earlier
today. The company continues to maintain a low OPEX and cash burn despite intensifying
its preparations ahead of the upcoming phase III trial. With a strengthened financial outlook
through a convertible loan from Linc, the receival of the initial tranches from the investment
agreement with Yangtian and accelerated milestones payments, we argue that OncoZenge
is on a promising trajectory. We reiterate our fair value range (SEK3.5 – SEK26) with a base
case valuation of SEK11.5.
LÄS MER
